Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 30;10(4):1152-1162.
doi: 10.1016/j.ekir.2025.01.026. eCollection 2025 Apr.

Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes

Massini Merzkani  1 , Nyein Chann Wai Lynn  1 , Karen Flores  1 , Gaurav Rajashekar  1 , Kristin Progar  1 , Rowena Delos Santos  1 , John P Atkinson  2 , Daniel C Brennan  3 , Anuja Java  1
Affiliations

Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes

Massini Merzkani et al. Kidney Int Rep. .

Abstract

Introduction: Thrombotic microangiopathy (TMA), characterized by small-vessel thrombosis caused by endothelial injury, presents significant diagnostic and treatment challenges in kidney transplantation.

Methods: To investigate the factors associated with posttransplant TMA, we conducted a retrospective study of 3535 kidney transplant recipients at our center from 2008 to 2023.

Results: Sixty-eight patients were diagnosed with TMA, and 93% (63 of 68) underwent genetic testing. Patients were categorized into 3 groups based on the TMA etiology. Group 1 (n = 42, 62%) included patients with complement-mediated TMA associated with genetic or acquired complement abnormalities. These patients were younger and had a higher incidence of hypertension (HTN) or preeclampsia as the causes of end-stage kidney disease (ESKD). Notably, 33% of patients developed recurrent TMA, and approximately 78% of those with recurrent TMA lost their allografts. Group 2 (n = 14, 21%) had TMA associated with calcineurin inhibitors (CNIs) or ischemia-reperfusion injury (IRI), showing longer cold ischemia times (CITs) (19.9 ± 8.7 hours vs. 10.7 ± 8.9 hours; P = 0.0001) and a higher rate of delayed graft function (DGF) (43% vs. 13%, P = 0.0008) than the controls. Group 3 (n = 12, 17%) had TMA from diverse causes (infections or autoimmune disorders) and exhibited a poor response to anticomplement therapy. No genetic variants were identified in this group.

Conclusion: Our findings underscore the need for comprehensive pre and posttransplantation genetic testing to predict and manage the risk of TMA and prevent graft loss. CNIs may exacerbate the risk of posttransplant TMA in the presence of other complement-activating factors. Our study also highlights the importance of personalized strategies and early interventions based on the functional assessment of variants of uncertain significance (VUS).

Keywords: antibody-mediated rejection; calcineurin inhibitors; complement; genetics; kidney transplantation; thrombotic microangiopathy.

PubMed Disclaimer

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Moake J.L. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600. doi: 10.1056/NEJMra020528. - DOI - PubMed
    1. George J.N., Nester C.M. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654–666. doi: 10.1056/NEJMra1312353. - DOI - PubMed
    1. Palma L.M.P., Sridharan M., Sethi S. Complement in secondary thrombotic microangiopathy. Kidney Int Rep. 2020;6:11–23. doi: 10.1016/j.ekir.2020.10.009. - DOI - PMC - PubMed
    1. Werion A., Storms P., Zizi Y., et al. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soc Nephrol. 2023;18:881–891. doi: 10.2215/CJN.0000000000000182. - DOI - PMC - PubMed
    1. Nester C.M., Feldman D.L., Burwick R., et al. An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group. Kidney Int. 2024;106:326–336. - PubMed

LinkOut - more resources